Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sevoflurane + cyclopropofol
- Development stage
- Phase 4
- Lead developer
- Mengchang Yang
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
sevoflurane + cyclopropofol is a combination anesthetic regimen being evaluated for the prevention of postoperative nausea and vomiting (PONV). Sevoflurane is a widely used volatile inhalational anesthetic that induces and maintains general anesthesia by modulating GABA-A, glycine, and NMDA receptors. Cyclopropofol (also known as ciprofol or cyclophenol) is a novel intravenous sedative-hypnotic agent and a structural analogue of propofol, acting as a potent GABA-A receptor agonist. While sevoflurane is often associated with a higher incidence of PONV, propofol-based agents are known for their antiemetic effects. This combination, studied in trials led by Mengchang Yang (NCT05837156), aims to optimize anesthetic depth while mitigating emetic side effects in high-risk surgical patients.
- Brand names
- CiprofolSevoranePetane
- Other names
- heptaflurane + cyclophenolsevoflurane + ciprofolheptaflurane + cyclopropofolsevoflurane + cyclophenol
02
Targets
GABRR (GABA-A receptor subunit rho)Glycine receptorNMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on sevoflurane + cyclopropofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sevoflurane + cyclopropofol.